Оценка эффективности применения циклоспорина при псориазе

Автор: Круглова Л.С., Понич Е.С., Осина А.В., Грязева Н.В.

Журнал: Саратовский научно-медицинский журнал @ssmj

Статья в выпуске: 3 т.13, 2017 года.

Бесплатный доступ

Представлен обзор рандомизированных исследований, в которых приняли участие пациенты с тяжелым псориазом, показавших, что после 10-12 недель монотерапии циклоспорином отмечается снижение Индекса распространенности и тяжести псориаза (PASI). После достижения клинической ремиссии должно быть принято решение о постепенном снижении дозы циклоспорина до минимальной эффективной дозы либо же о полной отмене приема препарата. Одновременное применение циклоспорина и UVB на данный момент широко не изучено. Комбинированное применение метотрексата и циклоспорина успешно используется в терапии ревматоидного и псориатического артрита. Комбинированный прием циклоспорина и системных биологических препаратов должен быть использован в исключительных случаях тяжелых форм псориаза, не поддающихся другим видам лечения, и только в течение ограниченного времени.

Еще

Клиническая ремиссия, комбинированный прием, псориаз, циклоспорин

Короткий адрес: https://sciup.org/14918527

IDR: 14918527

Список литературы Оценка эффективности применения циклоспорина при псориазе

Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. Journal of Investigative Dermatology Symposium Proceedings 2004; 9 (2): 136-139
KimballAB, Gladman D, Gelfand JM, etal. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-1042
Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics 2012; 30 (11): 1005-1013
Laburte C, Grossman R, Abi-Rached J, et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. British Journal of Dermatology 1994; 130 (3): 366-375
Heydendael VMR, Spuls PI, Opmeer ВС. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. New England Journal of Medicine 2003; 349 (7): 658-665
Faerber L, Braeutigam M, Weidinger G. Cyclosporine in severe psoriasis: results of a meta-analysis in 579 patients. American Journal of Clinical Dermatology 2001; 2 (1): 41 -47
Colombo D, Flori L, Altomare G, et al. Clinical outcome evaluation following cyclosporine a treatment in moderate to severe psoriasis: a retrospective study. International Journal of Im-munopathology and Pharmacology 2010; 23 (1): 363-367
Знаменская Л.Ф. Яковлева С. В., Волнухин В. А, Пирогова Е.В. Современные методы терапии больных псориазом. Вестник дерматологии и венерологии 2011; 1: 11-14
Кунгуров H.B., Кохан M.M., Кениксфест Ю. В. Биологическая терапия больных тяжелыми формами псориаза. Вестник дерматологии и венерологии 2012;4:91-95
Кутасевич Я.Ф., Олейник И. А. Иммуносупрессивная терапия больных артропатическим псориазом: метод, рекомендации. Киев, 2011; 19 с.
Lee JS, Yun SJ, Lee JB, et al. The efficacy of cyclospo-rin in patients with atopic dermatitis. Korean J Dermatol 2008; 46: 224-230
Олисова О.Ю., Теплюк Н.П., Пенегин В. Б. Современные методы лечения псориаза. Русский медицинский журнал 2015; 9
Enerback С. Soluble biomarkers in psoriasis. Eur J Dermatol 2011; 21 (6): 844-50
Ho VC, Griffiths СЕМ, Albrecht G. Intermittent short courses of cyclosporin (Neoral) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. British Journal of Dermatology 1999; 141 (2): 283-291
Ellis CN, Fradin MS, Messana JM. Cyclosporine for plaque-type psoriasis: Results of a multidose, double-blind trial. New England Journal of Medicine 1991; 324 (5): 277-284
Thaci D, Brutigam M, Kaufmann R, et al. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis: A randomised study. Dermatology 2002; 205 (4): 383-388
Heydendael VMR, Spuls PI, Opmeer ВС. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. New England Journal of Medicine 2003; 349 (7): 658-665
Flytstn_(m I, Stenberg B, Svensson E, Bergbrant l-M. Methotrexate versus ciclosporin in psoriasis: effectiveness, quality of life and safety: A randomized controlled trial. British Journal of Dermatology 2008; 158 (1): 116-121
Meffert H, Brutigam M, Ferber L, Weidinger G. Low-dose (1.25mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Dermato-Venere-ologica 1997; 77 (2): 137-141
Christophers E, Mrowietz U, Henneicke H-H, et al. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. Journal of the American Academy of Dermatology 1992; 26 (1): 86-90
Mahrle G, Schulze H-J, Farber L. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. Journal of the American Academy of Dermatology 1995; 32 (1): 78-88
Faerber L, Braeutigam M, Weidinger G. Cylosporine in severe psoriasis: results of a meta-analysis in 579 patients. American Journal of Clinical Dermatology 2001; 2 (1): 41 -47
Powles AV, Hardman CM, Porter W, et al. Renal function after 10 years' treatment with cyclosporin for psoriasis. British Journal of Dermatology 1998; 138 (3): 443-449
Fradin MS, Ellis CN, Voorhees JJ. Rapid response of von Zumbusch psoriasis to cyclosporine. Journal of the American Academy of Dermatology 1990; 23 (5): 925-926
Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. Journal of the American Academy of Dermatology 2010; 62 (5): 838-853
Griffiths СЕМ, Dubertret L, Ellis CN. Cyclosporin in psoriasis clinical practice: an international consensus statement. British Journal of Dermatology 2004; 150 (67): 11-23
Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Short and long-term considerations conserning the management of claque psoriasis with low-dose cyclosporine. Dermatology 1993; 187(1): 19-29
Mrowietz U, Ferber L, Henneicke-Von Zepelin H-H. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. Journal of the American Academy of Dermatology 1995; 33 (3): 470-475
Ho VCY, Griffiths СЕМ, Berth-Jones J. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. Journal of the American Academy of Dermatology 2001; 44 (4): 643-651
Finzi AF. Individualized short-course cyclosporin therapy in psoriasis. British Journal of Dermatology. 1996; 135 (48):31-34
Okubo Y, Natsume S, Usui K, et al. Low-dose, short-term ciclosporin (Neoral) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients. Journal of Dermatology 2011; 38 (5): 465-472
Menter A, Korman NJ, Elmets CA. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. Journal of the American Academy of Dermatology 2009; 61 (3): 451-485
Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. Journal of the American Academy of Dermatology 2010; 63 (6): 949-972
Pathirana D, Ormerod AD, Saiag P. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereol-ogy2010;23(2): 1-70
Maza A, Montaudiy H, Sbidian E. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. Journal of the European Academy of Dermatology and Venereol-ogy2011;25(2): 19-27
Vena GA, Coviello C, Foti C, et al. Ciclosporina A nella psoriasi: mantenimento dell'efficacia con somministrazione inter-vallata. Chronica Dermatologica 1994; 4 (4): 639-645
Cassano N, Colombo D, Vena GA. Linee guida al trat-tamento con ciclosporina A: Stato deH'arte. Giornale Italiano di Dermatologia e Venereologia 2001; 136 (6): 463-470
Van de Kerkhof PCM. Therapeutic strategies: rotational therapy and combinations. Clinical and Experimental Dermatology 2001; 26 (4): 356-361
Muellenhoff MW, Koo JY Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience: A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. Journal of Dermatological Treatment 2012; 23 (4): 290-304
Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and bio-logics: facts and controversies. Clinics in Dermatology 2010; 28 (1): 88-92
Mazzanti G, Coloni L, De Sabbata G, Paladini G. Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis: A pilot study. Acta Dermato-Venereologica 1994; 186: 116-117
Tugwell P, Pincus T, Yocum D. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. New England Journal of Medicine 1995; 333 (3): 137-141
Stein CM, Pincus T, Yocum D. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. Arthritis and Rheumatism 1997; 40 (10): 1843-1851
Daly M, Alikhan A, Armstrong AW. Combination systemic therapies in psoriatic arthritis. Journal of Dermatological Treatment 2011; 22 (5): 276-284
Fraser AD, Van Kuijk AWR, Westhovens R. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Annals of the Rheumatic Diseases 2005; 64 (6); 859-864
Clark CM, Kirby B, Morris AD. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. British Journal of Dermatology 1999; 141 (2): 279-282
Lebwohl MM, Koo AJ, Feldman SR. Combination therapy to treat moderate to severe psoriasis. Journal of the American Academy of Dermatology 2004; 50 (3): 416-430
Aydin F, Canturk T, Senturk N, Turanli AY. Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clinical and Experimental Dermatology 2006; 31 (4): 520-524
Mohanan S, Ramassamy S, Chandrashekar L, Thap-pa DM. A retrospective analysis of combination methotrexate-cy-closporine therapy in moderate-severe psoriasis. Journal of Der-matological Treatment 2014; 25: 50-53
Korstanje MJ, Van Breda Vriesman CJP, Van de Staak WJBM. Cyclosporine and methotrexate: a dangerous combination. Journal of the American Academy of Dermatology 1990; 23 (2): 320-321
Roenigk JrHH. Acitretin combination therapy. Journal ofthe American Academy of Dermatology 1999; 41 (3): 18-21
Koo J, Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. Journal ofthe American Academy of Dermatology 1999; 41 (3): 25-28
Brechtel B, Wellenreuther U, Toppe E, Czarnetzki BM. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis. Journal of the American Academy of Dermatology 1994; 30 (6): 1023-1024
KuijpersALA, Van Dooren-Greebe RJ. Van de Kerkhof PCM. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with euythrodermic psoriasis. Dermatology 1997; 194(1): 88-90
Kokelj F, Plozzer C, Torsello P, Trevisan G. Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports). Journal ofthe European Academy of Dermatology and Venereology 1998; 11 (2): 177-179
Cassano N, Vena GA. Cyclosporine in the era of bio-logics: a mini-review with special emphasis on the possible use in combination with biologies for psoriasis. Clinical Dermatology 2013; 1 (1): 15-18
D'Angelo S, Cutro MS, Lubrano E, et al. Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis. Annals ofthe Rheumatic Diseases 2010; 69 (5): 934-935
Atzeni F, Boccassini L, Antivalle M, et al. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Annals ofthe Rheumatic Diseases 2011; 70 (4): 712-714
Karanikolas GN, Koukli E-M, Katsalira A. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonran-domized unblinded clinical trial. Journal of Rheumatology 2011; 38 (11): 2466-2474.

Еще

Статья научная